You are here

Cumulative Irritation Test

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
The Education and Research Foundation, Inc.
Lynchburg, Virginia, 24501 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tinea Pedis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subjects must meet all of the following criteria for inclusion in the study.

1. Healthy volunteers of either sex, at least 18 years of age or older.

2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically
sterile [bilateral oophorectomy and/or total hysterectomy]). All females must submit
to a urine pregnancy test and have a negative result at Day 1 and at the final study
visit.

3. Subjects may be of any skin type or race providing their degree of skin pigmentation
does not interfere with making readings of skin reactions.

4. Willingness to follow the study procedures and complete the study.

5. Written informed consent obtained.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Any skin disease that would in any way confound interpretation of the study results.
Atopic dermatitis/eczema, psoriasis will be excluded.

2. Chronic asthma will be excluded.

3. Pregnant or nursing mothers.

4. A history of sensitivity to any component of any of the formulations.

5. Use of chronic medications (such as antihistamines, corticosteroids, analgesics and
anti-inflammatories) for one week before and during the study.

NCT00781664
Pfizer
Completed
Cumulative Irritation Test

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Tinea Pedis
NCT00781664
All Genders
18+
Years
Lynchburg, Virginia
Tinea Capitis
NCT00645242
All Genders
3+
Years
Multiple Sites
Cumulative Irritation Test
21-Day Cumulative Irritation Test
The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.
Healthy, adult volunteers of either sex will be patched daily on his/her back with multiple strengths of AN2718 in 2 different topical dosage forms and an active comparator over the course of 21 consecutive days. Twenty-four hours after each application, the patches will be removed and the site evaluated using a five-point scale for irritation.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Tinea Pedis
  • Other: AN2718
    AN2718 Cream SF Vehicle, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Cream SF, 0.3%, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Cream SF, 1%, Daily for up to 21 days
  • Other: AN2718
    AN2718 Gel Vehicle, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Gel, 1.5%, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Gel, 2.5%, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Gel, 5%, Daily for up to 21 days
  • Drug: AN2718
    AN2718 Gel, 7.5%, Daily for up to 21 days
  • Other: Sodium Lauryl Sulfate
    Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
    Other Name: SLS
  • Experimental: A
    AN2718 Cream SF Vehicle
    Intervention: Other: AN2718
  • Experimental: B
    AN2718 Cream SF, 0.3%
    Intervention: Drug: AN2718
  • Experimental: C
    AN2718 Cream SF, 1%
    Intervention: Drug: AN2718
  • Experimental: D
    AN2718 Gel Vehicle
    Intervention: Other: AN2718
  • Experimental: E
    AN2718 Gel, 1.5%
    Intervention: Drug: AN2718
  • Experimental: F
    AN2718 Gel, 2.5%
    Intervention: Drug: AN2718
  • Experimental: G
    AN2718 Gel, 5%
    Intervention: Drug: AN2718
  • Experimental: H
    AN2718 Gel, 7.5%
    Intervention: Drug: AN2718
  • Active Comparator: I
    Sodium Lauryl Sulfate, 0.5%
    Intervention: Other: Sodium Lauryl Sulfate
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
November 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Subjects must meet all of the following criteria for inclusion in the study.

  1. Healthy volunteers of either sex, at least 18 years of age or older.
  2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically sterile [bilateral oophorectomy and/or total hysterectomy]). All females must submit to a urine pregnancy test and have a negative result at Day 1 and at the final study visit.
  3. Subjects may be of any skin type or race providing their degree of skin pigmentation does not interfere with making readings of skin reactions.
  4. Willingness to follow the study procedures and complete the study.
  5. Written informed consent obtained.

Exclusion Criteria:

  1. Any skin disease that would in any way confound interpretation of the study results. Atopic dermatitis/eczema, psoriasis will be excluded.
  2. Chronic asthma will be excluded.
  3. Pregnant or nursing mothers.
  4. A history of sensitivity to any component of any of the formulations.
  5. Use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00781664
AN2718-TP-101
No
Not Provided
Not Provided
Lee Zane, M.D., M.A.S., Anacor Pharmaceuticals, Inc.
Pfizer
Not Provided
Study Director: Lee Zane, M.D., M.A.S. Pfizer
Pfizer
November 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now